1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Anaeropharma Co-Opts Microbe For Targeted Fight Against Hypoxic Tumors

 
• By Ian Haydock

Japanese venture Anaeropharma Science is working on a unique approach to targeted drug delivery it says confers advantages including fewer systemic side effects, and the technology is already seeing validation through several research deals with major Japanese pharma companies.

President and CEO Tetsuya Mishima and Director, Strategic Alliances Dr Li Wang
Anaeropharma Science President & CEO Tetsuya Mishima (left) and Director, Strategic Alliances, Dr Li Wang. • Source: Anaeropharma Science

Founded in 2004 and now with around 20 employees, privately held Japanese venture Anaeropharma Science Inc. is pursuing what it says is a novel approach globally to the bacteria-mediated delivery of therapeutics to solid tumors.

The Tokyo-based company has developed its proprietary i-DPS (in situ Delivery and Production System) platform based around recombinant Bifidobacterium longum, a non-pathogenic, anaerobe gut bacterium found naturally in the body

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.